Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FINESSE-CKD
2023-506434-69-00Phase 2Completed
- Sponsor
- University Medical Center Groningen
- Start
- Feb 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides, Small Molecules
- Countries
- 4
01
Overview
Phase 2, single-arm trial of finerenone and semaglutide in chronic kidney disease (CKD), sponsored by University Medical Center Groningen. Primary endpoint: Percentage change from baseline in UACR. Started Feb 2025; status: completed.
02
Drugs
finerenonesemaglutide
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2023-506434-69-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506434-69-00.